Efficacy and cost-efficacy of biologic therapies for moderate to severe psoriasis: A meta-analysis and cost-efficacy analysis using the intention-to-treat principle

BioMed Research International

Volumn 2014, Issue , 2014, Pages

  Chi, Ching Chi ^a,b   Wang, Shu Hui ^c,d  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^b CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^c FAR EASTERN MEMORIAL HOSPITAL   (Taiwan)

^d ORIENTAL INSTITUTE OF TECHNOLOGY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ETANERCEPT; INFLIXIMAB; USTEKINUMAB; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; TNFR FC FUSION PROTEIN; TNFR-FC FUSION PROTEIN; TUMOR NECROSIS FACTOR RECEPTOR;

ARTICLE; BIOLOGICAL THERAPY; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; HUMAN; INTENTION TO TREAT ANALYSIS; INTERVENTION STUDY; META ANALYSIS; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; PHYSICIANS GLOBAL ASSESSMENT; PSORIASIS; PSORIASIS AREA AND SEVERITY INDEX; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK REDUCTION; COST BENEFIT ANALYSIS; ECONOMICS; PATHOLOGY; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; BIOLOGICAL THERAPY; COST-BENEFIT ANALYSIS; HUMANS; IMMUNOGLOBULIN G; INTENTION TO TREAT ANALYSIS; PSORIASIS; RECEPTORS, TUMOR NECROSIS FACTOR; TREATMENT OUTCOME;

EID: 84896836824     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2014/862851     Document Type: Article

References (31)

1. Beyer V., Wolverton S. E., Recent trends in systemic psoriasis treatment costs. Archives of Dermatology 2010 146 1 46 54 2-s2.0-74549221523 10.1001/archdermatol.2009.319
2. Prescribing InFormation for Enbrel 2011 Thousand Oaks, Calif, USA Immunex Corporation
3. Prescribing InFormation for Humira 2012 North Chicago, Ill, USA Abbott Laboratories
4. Prescribing InFormation for Remicade 2011 Horsham, UK Janssen Biotech
5. Prescribing InFormation for Stelara 2012 Horsham, UK Janssen Biotech
6. Schafer J. A., Kjesbo N. K., Gleason P. P., Formulary review of 2 new biologic agents: tocilizumab for rheumatoid arthritis and ustekinumab for plaque psoriasis. Journal of Managed Care Pharmacy 2010 16 6 402 416 2-s2.0-77957270719
7. Anthem Insurance Companies, Medical Policy on ustekinumab. October 2012, http://www.anthem.com/medicalpolicies/policies/mp-pw-c120021.htm
8. Higgins J. P. T., Green S., Cochrane Handbook for Systematic Reviews of Interventions 2008 Chichester, UK Wiley-Blackwell
9. Papp K. A., Tyring S., Lahfa M., Prinz J., Griffiths C. E. M., Nakanishi A. M., Zitnik R., Van De Kerkhof P. C. M., A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction. British Journal of Dermatology 2005 152 6 1304 1312 2-s2.0-21644481166 10.1111/j.1365-2133.2005.06688.x
10. Gordon K. B., Langley R. G., Leonardi C., Toth D., Menter M. A., Kang S., Heffernan M., Miller B., Hamlin R., Lim L., Zhong J., Hoffman R., Okun M. M., Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study. Journal of the American Academy of Dermatology 2006 55 4 598 606 2-s2.0-33748936662 10.1016/j.jaad.2006.05.027
11. Leonardi C. L., Kimball A. B., Papp K. A., Yeilding N., Guzzo C., Wang Y., Li S., Dooley L. T., Gordon K. B., Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). The Lancet 2008 371 9625 1665 1674 2-s2.0-43449111187 10.1016/S0140-6736(08) 60725-4
12. Menter A., Tyring S. K., Gordon K., Kimball A. B., Leonardi C. L., Langley R. G., Strober B. E., Kaul M., Gu Y., Okun M., Papp K., Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial. Journal of the American Academy of Dermatology 2008 58 1 106 115 2-s2.0-37349003068 10.1016/j.jaad.2007.09.010
13. Papp K. A., Langley R. G., Lebwohl M., Krueger G. G., Szapary P., Yeilding N., Guzzo C., Hsu M.-C., Wang Y., Li S., Dooley L. T., Reich K., Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). The Lancet 2008 371 9625 1675 1684 2-s2.0-43449139402 10.1016/S0140-6736(08)60726-6
14. Asahina A., Nakagawa H., Etoh T., Ohtsuki M., Adalimumab in Japanese patients with moderate to severe chronic plaque psoriasis: efficacy and safety results from a Phase II/III randomized controlled study. Journal of Dermatology 2010 37 4 299 310 2-s2.0-77950206670 10.1111/j.1346-8138.2009.00748.x
15. Reich K., Nestle F. O., Papp K., Ortonne J.-P., Evans R., Guzzo C., Li S., Dooley L. T., Griffiths C. E. M., Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet 2005 366 9494 1367 1374 2-s2.0-26644433889 10.1016/S0140-6736(05) 67566-6
16. Menter A., Feldman S. R., Weinstein G. D., Papp K., Evans R., Guzzo C., Li S., Dooley L. T., Arnold C., Gottlieb A. B., A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis. Journal of the American Academy of Dermatology 2007 56 1 31.e1 31.e15 2-s2.0-33845692734 10.1016/j.jaad.2006.07.017
17. Torii H., Nakagawa H., Infliximab monotherapy in Japanese patients with moderate-to-severe plaque psoriasis and psoriatic arthritis. A randomized, double-blind, placebo-controlled multicenter trial. Journal of Dermatological Science 2010 59 1 40 49 2-s2.0-77953616679 10.1016/j.jdermsci.2010.04.014
18. Tsai T.-F., Ho J.-C., Song M., Szapary P., Guzzo C., Shen Y.-K., Li S., Kim K.-J., Kim T.-Y., Choi J.-H., Youn J.-I., Efficacy and safety of ustekinumab for the treatment of moderate-to-severe psoriasis: a phase III, randomized, placebo-controlled trial in Taiwanese and Korean patients (PEARL). Journal of Dermatological Science 2011 63 3 154 163 2-s2.0-79961030711 10.1016/j.jdermsci. 2011.05.005
19. Bagel J., Lynde C., Tyring S., Kricorian G., Shi Y., Klekotka P., Moderate to severe plaque psoriasis with scalp involvement: a randomized, double-blind, placebo-controlled study of etanercept. Journal of the American Academy of Dermatology 2012 67 1 86 92 2-s2.0-80054094698 10.1016/j.jaad.2011. 07.034
20. Igarashi A., Kato T., Kato M., Song M., Nakagawa H., Efficacy and safety of ustekinumab in Japanese patients with moderate-to-severe plaque-type psoriasis: long-term results from a phase 2/3 clinical trial. Journal of Dermatology 2012 39 3 242 252 2-s2.0-84857623641 10.1111/j.1346-8138.2011.01347. x
21. Zheng M., Zhu X. J., Song M., A randomized, double-blind, placebo-controlled study of ustekinumab in Chinese patients with moderate to severe plaque psoriasis: LOTUS trial results. Journal of Dermatology 2012 39 supplement 1 238 239
22. Rapp S. R., Feldman S. R., Exum M. L., Fleischer A. B., Reboussin D. M., Psoriasis causes as much disability as other major medical diseases. Journal of the American Academy of Dermatology 1999 41 3 401 407 2-s2.0-0032872277 10.1016/S0190-9622(99)70112-X
23. Ferrándiz C., García A., Blasco A. J., Lázaro P., Cost-efficacy of adalimumab, etanercept, infliximab and ustekinumab for moderate-to-severe plaque psoriasis. Journal of the European Academy of Dermatology and Venereology 2012 26 6 768 777 2-s2.0-82255166955 10.1111/j.1468-3083.2011.04357.x
24. Greiner R.-A., Braathen L. R., Cost-effectiveness of biologics for moderate-to-severe psoriasis from the perspective of the Swiss healthcare system. European Journal of Dermatology 2009 19 5 494 499 2-s2.0-69849092173 10.1684/ejd.2009.0725
25. Anis A. H., Bansback N., Sizto S., Gupta S. R., Willian M. K., Feldman S. R., Economic evaluation of biologic therapies for the treatment of moderate to severe psoriasis in the United States. Journal of Dermatological Treatment 2011 22 2 65 74 2-s2.0-79952414029 10.3109/09546630903551258
26. Sizto S., Bansback N., Feldman S. R., Willian M. K., Anis A. H., Economic evaluation of systemic therapies for moderate to severe psoriasis. British Journal of Dermatology 2009 160 6 1264 1272 2-s2.0-66149110602 10.1111/j.1365-2133.2008.08962.x
27. Colombo G. L., Di Matteo S., Peris K., Fargnoli M. C., Esposito M., Mazzotta A., Chimenti S., A cost-utility analysis of etanercept for the treatment of moderate-to-severe psoriasis in Italy. ClinicoEconomics and Outcomes Research 2009 1 1 53 59 2-s2.0-77953460695
28. Driessen R. J. B., Bisschops L. A., Adang E. M. M., The economic impact of high-need psoriasis in daily clinical practice before and after the introduction of biologics. British Journal of Dermatology 2010 162 6 1324 1329 2-s2.0-77952695421 10.1111/j.1365-2133.2010.09693.x
29. Chi C. C., Evidence-based dermatology. Dermatologica Sinica 2013 31 1 2 6
30. Ash Z., Gaujoux-Viala C., Gossec L., Hensor E. M. A., FitzGerald O., Winthrop K., Van Der Heijde D., Emery P., Smolen J. S., Marzo-Ortega H., A systematic literature review of drug therapies for the treatment of psoriatic arthritis: current evidence and meta-analysis informing the EULAR recommendations for the management of psoriatic arthritis. Annals of the Rheumatic Diseases 2012 71 3 319 326 2-s2.0-84857238069 10.1136/ard.2011.150995
31. Gottlieb A., Menter A., Mendelsohn A., Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial. The Lancet 2010 376 9752 1542 2-s2.0-78149286841 10.1016/S0140-6736(10)62033-8